Bivalirudin: Uses, Mechanism, and Reported Side Effects

Key takeaways

• Bivalirudin is a direct thrombin inhibitor used as an anticoagulant during certain heart procedures.
• It is approved for patients undergoing percutaneous coronary intervention (PCI), including those with heparin-induced thrombocytopenia.
• More than 100 registered trials have studied bivalirudin, including completed phase 3 work in bypass surgery patients.
• The most reported adverse events involve bleeding and clotting complications, including hemorrhage and stent thrombosis.
• Its label does not carry a boxed warning.

What Bivalirudin Is

Bivalirudin belongs to a class of medicines called direct thrombin inhibitors, classified on its label as an anticoagulant. It works by binding directly to thrombin, a protein that drives blood clot formation. By attaching to both the active site and a separate binding region on thrombin, bivalirudin blocks thrombin from converting fibrinogen into fibrin, the mesh that stabilizes a clot. This also limits thrombin's ability to activate other clotting factors that reinforce the clot structure. Bivalirudin has a PubChem CID of 16129704.

What Bivalirudin Is Approved For

Bivalirudin, marketed under its own generic name, is approved as an anticoagulant for patients undergoing percutaneous coronary intervention. This includes patients who have heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS), conditions that can complicate the use of heparin-based anticoagulants. The label does not include a boxed warning.

What the Evidence Shows

Bivalirudin has been studied in 106 registered clinical trials. One completed phase 3 trial, the CHOOSE study, evaluated bivalirudin in patients with HIT or HITTS undergoing off-pump coronary artery bypass grafting. Other research includes an active substudy examining coronary microvascular dysfunction and an imaging substudy tied to the MATRIX trial.

Reported Side Effects

Reported adverse events for bivalirudin, drawn from FAERS reports, reflect counts of submitted reports rather than confirmed incidence or proven causation. The most frequently reported terms describe bleeding and clotting problems: hemorrhage (91 reports), gastrointestinal hemorrhage (45), thrombosis (44), and vascular stent thrombosis (40). Heparin-induced thrombocytopenia (76 reports) and acute myocardial infarction (36) were also commonly reported, alongside general reports of drug ineffectiveness (200) and off-label use (114).